C5 and paroxysmal nocturnal hemoglobinuria: Anti-complement treatment with the anti-C5 monoclonal antibody eculizumab results in sustained inhibition of complement-mediated hemolysis in almost all PNH patients (19, 20); however, in the registration trials the endpoints were mostly set on transfusion independence and reduction of hemolysis, assessed by LDH.